Target intelligence / Profile preview

Japanese encephalitis virus structural proteins other than E (JEV C and prM/M)

Target
JEV C and prM/M
Molecular classification
Viral structural protein, RNA-binding protein, Chaperone
01

Overview

The Japanese encephalitis virus (JEV) structural proteins other than the envelope (E) protein consist of the capsid (C) and the pre-membrane (prM) proteins. The C protein is a small, highly basic protein that binds to the viral RNA genome to form the nucleocapsid, which is essential for viral assembly and the protection of the viral genome (Source 1.2.4, 1.4.2). It also interacts with host factors such as lipid droplets and the autophagy-related protein LC3-I to facilitate viral replication and pathogenesis (Source 1.4.3). The prM protein acts as a chaperone for the E protein, ensuring its proper folding and preventing premature fusion within the acidic environment of the host's secretory pathway (Source 1.2.2, 1.3.3). During the maturation of the virus, prM is cleaved by the host protease furin into the membrane (M) protein and a "pr" peptide, which is released upon virion exit (Source 1.1.1, 1.2.1). Both C and prM are considered potential therapeutic targets; research has explored inhibitors of nucleocapsid assembly (such as ST-148 analogs) and maturation processes (such as furin inhibitors) to block JEV infection (Source 1.2.4, 1.4.1).

Other names
Japanese encephalitis virus capsid proteinJapanese encephalitis virus pre-membrane proteinJEV C proteinJEV prM proteinJEV M proteinJEV core proteinJEV structural proteins (non-E)
02

Mechanism of action

Inhibition of nucleocapsid assembly by targeting the C protein and prevention of viral maturation by inhibiting prM cleavage.

03

Biological functions

Viral assemblyNucleocapsid formationViral maturationRNA bindingProtein foldingNeuroinvasion
04

Disease associations

InfectionJapanese encephalitis
05

Safety considerations

Off-target effects on host proteases (e.g., furin)Viral resistance mutationsPotential for antibody-dependent enhancement (ADE) if sub-neutralizing antibodies are produced against prM
06

Interacting drugs

ST-148

2 more in the full profile.

07

Biomarkers

JEV RNAAnti-prM antibodiesJEV prM protein levelsViral titer

Beyond the preview

Go deeper on Japanese encephalitis virus structural proteins other than E (JEV C and prM/M).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Japanese encephalitis virus structural proteins other than E (JEV C and prM/M).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call